About Us

Dr. Jennifer Gudeman was appointed Vice President, Medical and Clinical Affairs, in December 2020. Prior to joining Avadel, Jennifer was Vice President, Medical Affairs, at AMAG Pharmaceuticals, overseeing a team of medical science liaisons and scientific communications. Prior to her time at AMAG Pharmaceuticals, she was Director of Medical Affairs at Lumara Health, a specialty branded pharmaceutical company focused on women's health, and previously served at Mallinckrodt Pharmaceuticals. During her career, she has led or contributed to six commercial product launches and three clinical development programs, as well as led interactions with medical societies and patient advocacy organizations to help ensure that commercial medications fulfill their clinically proven therapeutic benefits to patients and providers. Jennifer has published numerous peer-reviewed papers and provided domestic and international presentations on partnership with industry for drug development in high-risk pregnancies. She graduated summa cum laude with a bachelor's degree in pharmacy and magna cum laude with a doctorate in pharmacy from St. Louis College of Pharmacy.

Richard Kim was appointed Chief Commercial Officer in February 2021. Prior to joining Avadel, he served as the President of US Commercial & Strategic Marketing at Intercept Pharmaceuticals, Inc. During his time there, he helped to successfully launch OCALIVA^™ (obeticholic acid), the first new treatment in nearly 20 years for the orphan disease primary biliary cholangitis, and led the launch strategy for NASH. Before Intercept, Richard served as General Manager, Hepatitis C Worldwide Commercialization, at Bristol-Myers Squibb, where he led the successful worldwide launch of DAKLINZA^™ (daclatasvir). Prior to this, he held several roles of increasing responsibility leading sales, operational, and strategic marketing teams at Bristol-Myers Squibb, including Vice President, SPRYCEL^™ Brand Lead, Oncology Global Marketing; Vice President, US In-Line Oncology and Global Marketing; and Vice President, East Area Sales, Cardiovascular and Metabolics. Prior to his time at Bristol-Myers Squibb, Richard held a range of senior positions in the US, Canada, and Australia at Schering-Plough, which was acquired by Merck & Co., Inc. Richard received a bachelor's degree in chemistry from the University of Alberta.

Scott Macke joined Avadel in November 2010 and has more than 25 years of pharmaceutical industry experience with a strong focus on both supply chain and project management. Prior to Avadel, Scott held roles of increasing responsibility at KV Pharmaceuticals, including Senior Director, Project Management, where he led the company's PMO, and at Mallinckrodt Pharmaceuticals where he began his career as a peptide chemist before moving into roles that included marketing (new products, active pharmaceutical ingredients) and drug product project management. Scott received his BS (biology) from Southwest Missouri State and a Master of Business Administration from Maryville University.

Thomas McHugh was appointed Chief Financial Officer in December 2019. Prior to joining Avadel, Tom served as Senior Vice President of Finance of Ironshore Pharmaceuticals Inc., where he built and led the US finance, accounting, and treasury functions and supported Ironshore's new product launch. Before his time at lronshore, Tom was the Chief Financial Officer and Treasurer at Lumara Health, a specialty branded pharmaceutical company focused on women's health. While at Lumara he supported a number of key strategic initiatives, including a new product launch, a restructuring, and a sale of the company. Prior to joining Lumara, Tom was a Managing Director and Global Controller at BearingPoint, a global consultancy, and prior to that, served as Chief Financial Officer at Huttig Building Products, Inc. Tom began his career in public accounting at PricewaterhouseCoopers. He earned his bachelor's degree in finance from Bentley University and a master's degree in accounting from Northeastern University.

Jerad G. Seurer is the General Counsel and Corporate Secretary, as well as the Compliance Officer, for Avadel Pharmaceuticals. Jerad joined Avadel in 2017 after approximately 13 years at Mallinckrodt Pharmaceuticals, where he held numerous positions, including Group General Counsel for the Generics/API business, as well as Vice President of Integration Management. Prior to Mallinckrodt, Jerad was in private legal practice at Wyatt Tarrant & Combs, Marsh Fischmann & Breyfogle, and Wilhelm Law Service. Jerad is currently licensed in Missouri, Minnesota, South Dakota, Wisconsin (inactive), and the United States Patent & Trademark Office. He received a BS in biology, Master of Arts in biology, and Juris Doctorate in law from the University of South Dakota.

Rosemarie Tully is a registered pharmacist with more than 20 years of pharma, drug delivery, biotech and medical device industry experience. Most recently, Rosemarie was Chief Operating Officer at Neuromod Devices Limited, a breakthrough neuromodulation company focused on the unmet needs of patients with chronic neurological conditions, including tinnitus. Previously, Rosemarie held senior roles in corporate development and strategy at Sigmoid Pharma Limited, Elan Corporation plc (now Perrigo Company plc), and was a management consultant at McKinsey & Company. Rosemarie has extensive operational leadership, fundraising, corporate business development and licensing experience. Rosemarie completed her BSc (Hons) Pharmacy degree at Trinity College Dublin, Ireland, and her master's degree in business administration at INSEAD, France.

Prior to joining Avadel in December 2019, Dr. Jason Vaughn was Principal at Wyatt Pharma Consulting, LLC, where he led several development programs for client companies, including Avadel. Before Wyatt Pharma, he was Senior Director and Vice President, Process Technology Development, for the North American region of Patheon Pharmaceuticals, a ThermoFisher Scientific company, where he was responsible for assisting client companies in product development, scale-up, and commercialization. Jason also served as Vice President, Pharmaceutical Development, for Banner Life Sciences, a specialty pharmaceutical company focused on developing products using the 505(b)2 pathway. There, he led a technical team developing a number of oral, modified-release products for IND-enabled clinical studies, registration, scale-up, NDA regulatory submission, and commercialization readiness for products, including Bafiertam™. Prior to Banner, Jason served as Director, Formulation Development, for Patheon Pharmaceuticals, leading teams focused on development, scale-up, registration, and commercialization of oral modified-release dosage. He received a BS in pharmacy and a PhD in pharmaceutics from the University of Texas at Austin.

Angie Woods was appointed Vice President, People and Culture, in May 2021. Angie has more than 25 years of experience in human resources, holding positions of increasing responsibility spanning multiple industries, global organizations, and diverse workforces. Prior to joining Avadel, Angie served as Vice President, Human Resources, at Mallinckrodt Pharmaceuticals, where she held various leadership roles over seven years with oversight for developing and leading people and talent strategies in support of the company's launch of new products, multiple M&A integrations, culture building, and business transformation. Prior to Mallinckrodt, Angie was Vice President, Human Resources, at Furniture Brands International, during which time she led a team of HR professionals to align and implement people and talent strategies in support of the transformation of the global manufacturing and supply chain organization, as well as the Designer Brands business from product design through delivery to the customer. Angie received a bachelor's degree in finance from Southern Illinois University, Carbondale.